Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation

Incyte ($INCY) announced an update on their ongoing clinical study. Incyte’s latest clinical update centers on a Phase 0 observational study titled...

Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report), SI-Bone (SIBN – R...

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH)

Incyte ($INCY) announced an update on their ongoing clinical study. Incyte’s Povorcitinib Trial Marks Progress in Treating Painful Skin Disorder HS...

Incyte’s Phase 3 Povorcitinib Study in Hidradenitis Suppurativa Reaches Completion, Setting Up Key Catalyst for INCY Investors

Exchange-traded funds (ETFs) offer a huge—and often confusing—number of choices. TipRanks’ ETF AI Analyst narrows it down to three ETFs with Outper...

3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026

Incyte ($INCY) announced an update on their ongoing clinical study. Incyte Clinical Study Sheds Light on New Drug’s Early Safety Profile The study,...

Incyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Incyte, with a price target of $116.00. The company’s sha...

Wells Fargo Remains a Buy on Incyte (INCY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Argenx Se (ARGX – Research Report) and Incyte (INC...

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Incyte (INCY)

BMO Capital analyst Evan Seigerman maintained a Sell rating on Incyte on January 2 and set a price target of $75.00. The company’s shares closed ye...

BMO Capital Remains a Sell on Incyte (INCY)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Incyte, with a price target of $115.00. According to TipRanks, Da...

Incyte (INCY) Gets a Buy from Barclays

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte, with a price target of $101.00. Frahm covers the Healthcare...

TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)

Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Incyte today and set a price target of $103.00. Devarakonda covers the He...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INCY	$102.24	-3.74%	1.36M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INCY	$102.24	-3.7%	1.36M
3
4
5
6

INCY

INCY

Get Incyte Corporation Data in Excel

Get Incyte Corporation Data in Excel